The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.
 
Haruko Daga
Honoraria - Chugai/Roche; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Janssen; Kyorin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst)
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Guardant Health AMEA; Illumina; Kyorin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Kyorin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Chugai Pharma; MSD
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Novartis
 
Ryo Toyozawa
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Masahiro Kodani
No Relationships to Disclose
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Pfizer; Roche
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD K.K. (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Yoshihiro Hattori
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Janssen (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Masahiro Morise
Speakers' Bureau - AstraZeneca; Chugai/Roche; Lilly; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Takaya Ikeda
No Relationships to Disclose
 
Shingo Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; Guardant Health; Novartis; Pfizer; Thermo Fisher Scientific
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kirin Pharmaceuticals; Lilly Japan; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Chugai Pharma; Pfizer
Research Funding - Amgen Astellas BioPharma (Inst)
 
Koichi Goto
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; MSD K.K.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo